세계의 말라리아 및 겸상적혈구병 치료제 시장 : 부문별, 국가 및 지역별 : 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

REPORT HIGHLIGHT

Malaria and Sickle Cell Disease Treatment Market size was valued at USD 5,611.36 million in 2023, expanding at a CAGR of 25.9% from 2024 to 2032.

The Malaria and Sickle Cell Disease Treatment Market refers to the industry segment focused on the development and provision of therapies and interventions for combating malaria and managing sickle cell disease. The persistent global burden of malaria, particularly in tropical and subtropical regions, driving investments in research and development for innovative treatments and preventive measures. Additionally, the growing prevalence of sickle cell disease, especially in regions with high malaria transmission rates, further fuels market growth, prompting efforts to enhance disease management and develop curative therapies. However, restraints include the challenge of drug resistance in malaria treatment and the complexity of sickle cell disease management, compounded by limited access to healthcare in resource-constrained settings. Nevertheless, opportunities abound with advancements in precision medicine and gene therapy, promising novel approaches for personalized treatment and potential cures, thereby driving innovation and market expansion in the malaria and sickle cell disease treatment landscape.

Malaria and Sickle Cell Disease Treatment Market- Market Dynamics

Advancements in Treating Malaria and Sickle Cell Disease Amidst High Prevalence

Advancements in treating malaria and sickle cell disease amidst high prevalence are crucial for addressing the significant global health burden posed by these conditions. For instance, according to the World Health Organization (WHO), malaria affects over 200 million people worldwide annually. According to the Sickle Cell Disease Coalition, an estimated 300,000 children are born annually with sickle cell disease (SCD) worldwide. This number is expected to increase to 400,000 by 2050. In response, organizations like the National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation are investing in research initiatives aimed at developing innovative treatments and preventive strategies. Recent breakthroughs include the approval of new antimalarial drugs like tafenoquine and the emergence of promising gene-editing therapies for sickle cell disease, underscoring the potential of advancements in healthcare to alleviate the burden of these diseases on affected populations worldwide.

Malaria and Sickle Cell Disease Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 25.9% over the forecast period (2024-2032)

Based on Disease segmentation, Sickle Cell Disease was predicted to show maximum market share in the year 2023

Based on Drug Type segmentation, Antimalarial Drugs was the leading type in 2023

Based on region, Asia Pacific was the leading revenue generator in 2023

Malaria and Sickle Cell Disease Treatment Market- Segmentation Analysis:

The Global Malaria and Sickle Cell Disease Treatment Market is segmented based on Disease, Drug Type, Route of Administration, and Region.

The market is divided into two categories based on Disease: Malaria and Sickle cell disease. Malaria prioritizes fast-acting drugs to combat rising cases and resistance, focusing on high-burden regions. Conversely, the sickle cell segment targets long-term management of chronic symptoms and improving patients' quality of life.

The market is divided into three categories based on Drug Type: Antimalarial Drugs, Pain Management Drugs, and Disease-Modifying Therapies. Antimalarial drugs dominate, targeting the parasite itself. Pain management drugs address a key symptom of sickle cell disease. The most promising segment is disease-modifying therapies, offering the potential to slow disease progression and improve long-term outcomes.

Malaria and Sickle Cell Disease Treatment Market- Geographical Insights

The Malaria and Sickle Cell Disease Treatment Market exhibits diverse patterns, with significant activity concentrated in regions disproportionately affected by these diseases, particularly in sub-Saharan Africa and parts of Southeast Asia. In Africa, where malaria is endemic and sickle cell disease prevalence is high, initiatives like the Roll Back Malaria Partnership and national malaria control programs drive demand for treatments and interventions. Additionally, efforts to improve access to healthcare and strengthen healthcare infrastructure contribute to market growth in these regions. In Southeast Asia, countries like India and Indonesia grapple with significant malaria burdens, while sickle cell disease remains a concern in countries with large populations such as India and Nigeria. These regions collectively represent key markets for malaria and sickle cell disease treatments, with opportunities for market expansion driven by ongoing efforts to combat these diseases and improve healthcare access and delivery.

Malaria and Sickle Cell Disease Treatment Market- Competitive Landscape:

The Malaria and Sickle Cell Disease treatment market is a battlefield for pharmaceutical giants like Pfizer, Novartis, and Sanofi. These companies are constantly innovating to stay ahead, with strategies like launching new drugs (e.g., Novartis' once-daily malaria treatment), acquiring promising companies (e.g., Pfizer's acquisition of sickle cell therapy leader Global Blood Therapeutics), and investing heavily in R&D for next-generation solutions. This fierce competition is good news for patients, as it translates into a constant flow of improved medications, easier treatment regimens, and hopefully, breakthroughs that address unmet needs in both diseases.

Recent Developments:

In September 2022, Vertex Pharmaceuticals and CRISPR Therapeutics launched a gene therapy called "exa-cel" for treating sickle cell disease. The treatment involves permanently changing DNA in a patient's blood cells to help the body produce a fetal form of hemoglobin, which is naturally present at birth but switches to an adult form that is defective in people with sickle cell disease.

In December 2023, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AbbVie Inc.

Alexion Pharmaceuticals, Inc. (acquired by AstraZeneca)

Bluebird Bio Inc.

Celgene Corporation (acquired by Bristol Myers Squibb)

Emmaus Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd

Gilead Sciences, Inc.

GlaxoSmithKline plc

Johnson & Johnson

MacroGenics, Inc.

Merck & Co., Inc.

Novartis International AG

Pfizer Inc.

Sanofi S.A.

Sobi

Vertex Pharmaceuticals Incorporated

Others

GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

• Malaria
• Sickle cell disease

GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

• Antimalarial Drugs
• Pain Management Drugs
• Disease-Modifying Therapies
• Other

GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

• Oral
• Parenteral

GLOBAL MALARIA AND SICKLE CELL DISEASE TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Malaria and Sickle Cell Disease Treatment Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Malaria and Sickle Cell Disease Treatment Market Snippet by Disease
  • 2.1.2. Malaria and Sickle Cell Disease Treatment Market Snippet by Drug Type
  • 2.1.3. Malaria and Sickle Cell Disease Treatment Market Snippet by Route of Administration
  • 2.1.4. Malaria and Sickle Cell Disease Treatment Market Snippet by Country
  • 2.1.5. Malaria and Sickle Cell Disease Treatment Market Snippet by Region
• 2.2. Competitive Insights

3. Malaria and Sickle Cell Disease Treatment Key Market Trends

• 3.1. Malaria and Sickle Cell Disease Treatment Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Malaria and Sickle Cell Disease Treatment Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Malaria and Sickle Cell Disease Treatment Market Opportunities
• 3.4. Malaria and Sickle Cell Disease Treatment Market Future Trends

4. Malaria and Sickle Cell Disease Treatment Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Malaria and Sickle Cell Disease Treatment Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Malaria and Sickle Cell Disease Treatment Market Landscape

• 6.1. Malaria and Sickle Cell Disease Treatment Market Share Analysis, 2023
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Malaria and Sickle Cell Disease Treatment Market - By Disease

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Disease, 2023 & 2032 (%)
  • 7.1.2. Malaria
  • 7.1.3. Sickle cell disease

8. Malaria and Sickle Cell Disease Treatment Market - By Drug Type

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
  • 8.1.2. Antimalarial Drugs
  • 8.1.3. Pain Management Drugs
  • 8.1.4. Disease-Modifying Therapies
  • 8.1.5. Other

9. Malaria and Sickle Cell Disease Treatment Market - By Route of Administration

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
  • 9.1.2. Oral
  • 9.1.3. Parenteral

10. Malaria and Sickle Cell Disease Treatment Market- By Geography

• 10.1. Introduction
  • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
• 10.2. North America
  • 10.2.1. Overview
  • 10.2.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in North America
  • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.2.4. North America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.2.7. U.S.
    • 10.2.7.1. Overview
    • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.7.3. U.S. Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.7.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.7.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.2.8. Canada
    • 10.2.8.1. Overview
    • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.2.8.3. Canada Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.2.8.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.2.8.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
• 10.3. Europe
  • 10.3.1. Overview
  • 10.3.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in Europe
  • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.3.4. Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.7. Germany
    • 10.3.7.1. Overview
    • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.7.3. Germany Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.7.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.7.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.8. Italy
    • 10.3.8.1. Overview
    • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.8.3. Italy Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.8.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.8.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.9. United Kingdom
    • 10.3.9.1. Overview
    • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.9.3. United Kingdom Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.9.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.9.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.10. France
    • 10.3.10.1. Overview
    • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.10.3. France Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.10.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.10.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.11. Russia
    • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.11.2. Russia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.11.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.11.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.12. Netherlands
    • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.12.2. Netherlands Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.12.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.12.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.13. Sweden
    • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.13.2. Sweden Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.13.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.13.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.14. Poland
    • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.14.2. Poland Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.14.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.14.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.3.15. Rest of Europe
    • 10.3.15.1. Overview
    • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
• 10.4. Asia Pacific (APAC)
  • 10.4.1. Overview
  • 10.4.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in Asia Pacific
  • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.4.4. Asia Pacific Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.7. India
    • 10.4.7.1. Overview
    • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.7.3. India Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.7.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.7.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.8. China
    • 10.4.8.1. Overview
    • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.8.3. China Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.8.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.8.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.9. Japan
    • 10.4.9.1. Overview
    • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.9.3. Japan Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.9.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.9.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.10. South Korea
    • 10.4.10.1. Overview
    • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.10.3. South Korea Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.10.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.10.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.11. Australia
    • 10.4.11.1. Overview
    • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.11.3. Australia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.11.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.11.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.12. Thailand
    • 10.4.12.1. Overview
    • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.12.3. Thailand Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.12.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.12.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.13. Indonesia
    • 10.4.13.1. Overview
    • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.13.3. Indonesia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.13.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.13.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.14. Philippines
    • 10.4.14.1. Overview
    • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.14.3. Philippines Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.14.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.14.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.4.15. Rest of APAC
    • 10.4.15.1. Overview
    • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.4.15.3. Rest of APAC Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.4.15.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.4.15.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
• 10.5. Latin America
  • 10.5.1. Overview
  • 10.5.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in Latin America
  • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.5.4. Latin America Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.5.7. Brazil
    • 10.5.7.1. Overview
    • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.7.3. Brazil Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.7.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.7.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.5.8. Mexico
    • 10.5.8.1. Overview
    • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.8.3. Mexico Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.8.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.8.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.5.9. Argentina
    • 10.5.9.1. Overview
    • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.9.3. Argentina Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.9.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.9.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.5.10. Colombia
    • 10.5.10.1. Overview
    • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.10.3. Colombia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.10.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.10.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.5.11. Rest of LATAM
    • 10.5.11.1. Overview
    • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
• 10.6. Middle East and Africa
  • 10.6.1. Overview
  • 10.6.2. Malaria and Sickle Cell Disease Treatment Key Manufacturers in Middle East and Africa
  • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
  • 10.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
  • 10.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  • 10.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6.7. Saudi Arabia
    • 10.6.7.1. Overview
    • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6.8. United Arab Emirates
    • 10.6.8.1. Overview
    • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6.9. Israel
    • 10.6.9.1. Overview
    • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.9.3. Israel Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.9.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.9.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6.10. Turkey
    • 10.6.10.1. Overview
    • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.10.3. Turkey Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.10.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.10.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6.11. Algeria
    • 10.6.11.1. Overview
    • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.11.3. Algeria Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.11.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.11.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6.12. Egypt
    • 10.6.12.1. Overview
    • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.12.3. Egypt Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.12.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.12.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  • 10.6.13. Rest of MEA
    • 10.6.13.1. Overview
    • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
    • 10.6.13.3. Rest of MEA Market Size and Forecast, By Disease, 2019 - 2032 (US$ Million)
    • 10.6.13.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 10.6.13.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Malaria and Sickle Cell Disease Treatment Industry

• 11.1. Competitive Dashboard
• 11.2. Company Profiles
  • 11.2.1. AbbVie Inc.
  • 11.2.2. Alexion Pharmaceuticals, Inc. (acquired by AstraZeneca)
  • 11.2.3. Bluebird bio Inc.
  • 11.2.4. Celgene Corporation (acquired by Bristol Myers Squibb)
  • 11.2.5. Emmaus Pharmaceuticals, Inc.
  • 11.2.6. F. Hoffmann-La Roche Ltd
  • 11.2.7. Gilead Sciences, Inc.
  • 11.2.8. GlaxoSmithKline plc
  • 11.2.9. Johnson & Johnson
  • 11.2.10. MacroGenics, Inc.
  • 11.2.11. Merck & Co., Inc.
  • 11.2.12. Novartis International AG
  • 11.2.13. Pfizer Inc.
  • 11.2.14. Sanofi S.A.
  • 11.2.15. Sobi
  • 11.2.16. Vertex Pharmaceuticals Incorporated
  • 11.2.17. Others

12. 360 Degree Analyst View

13. Appendix

• 13.1. Research Methodology
• 13.2. References
• 13.3. Abbreviations
• 13.4. Disclaimer
• 13.5. Contact Us